KEROS THERAPEUTICS INC (KROS:NASDAQ)
$11.12 -0.56 (-4.7945%)
Analysed KEROS THERAPEUTICS INC (KROS:NASDAQ) News Sources
Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates
14-05-2026
yahoo.com
Keros Therapeutics Reports Second Quarter 2026 Financial Results
03-08-2026
yahoo.com
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
24-08-2026
yahoo.com
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
24-08-2026
yahoo.com
Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?
03-04-2026
yahoo.com
Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20
17-05-2026
yahoo.com
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
01-06-2026
yahoo.com
Keros Therapeutics Appoints Anne Prener to its Board of Directors
25-06-2026
yahoo.com
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
30-07-2026
yahoo.com
Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?
14-08-2026
yahoo.com
What is the current price of KEROS THERAPEUTICS INC (KROS:NASDAQ)?
The current price of KEROS THERAPEUTICS INC (KROS:NASDAQ) is $11.12.
KEROS THERAPEUTICS INC (KROS:NASDAQ) absolute price change since previous trading day?
The absolute price change of KEROS THERAPEUTICS INC (KROS:NASDAQ) since the previous trading day is $-0.56.
KEROS THERAPEUTICS INC (KROS:NASDAQ) percentage price change since previous trading day?
The percentage price change of KEROS THERAPEUTICS INC (KROS:NASDAQ) since the previous trading day is -4.7945%.
What is the most recent average sentiment score for KEROS THERAPEUTICS INC (KROS:NASDAQ)?
The most recent average sentiment score for KEROS THERAPEUTICS INC (KROS:NASDAQ) is 77 out of 100.
What is the most recent average sentiment for KEROS THERAPEUTICS INC (KROS:NASDAQ)?
The most recent sentiment for KEROS THERAPEUTICS INC (KROS:NASDAQ) is .
SEC-8K** Filing Available For KEROS THERAPEUTICS INC (KROS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.